CA
CLDX icon

Corriente Advisors’s Celldex Therapeutics CLDX Stock Holding History

Corriente Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-460,000
Closed -$5.98M – 18
2020
Q2 		$5.98M Buy
+460,000
New +$2.04M 3.87% 9

Other funds holding CLDX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Corriente Advisors's CLDX Position: Q3 2020 in Review

Corriente Advisors sold out of Celldex Therapeutics (CLDX) in Q3 2020, closing a stake of 460,000 shares — an estimated $5.98M sold.

Corriente Advisors first reported a position in CLDX in Q2 2020 and held it in 1 quarter. The position peaked at $5.98M in Q2 2020. 91 funds tracked by Wall St. Rank hold CLDX as of Q3 2020.

  • Corriente Advisors reported no remaining Celldex Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Corriente Advisors sold 460,000 Celldex Therapeutics shares in Q3 2020, an estimated $5.98M.
  • Corriente Advisors first reported a position in Celldex Therapeutics in Q2 2020 and held it in 1 quarter.
  • Corriente Advisors's Celldex Therapeutics position peaked at $5.98M in Q2 2020.
  • 91 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2020.

Based on Corriente Advisors's 13F filing for Q3 2020, filed 3 Nov 2020.